Literature DB >> 31407522

Immunoengineering in glioblastoma imaging and therapy.

Steven Zanganeh1, Petrina Georgala1, Claudia Corbo2, Leila Arabi3, Jim Q Ho4, Najme Javdani5, Mohammad R Sepand6, Kiara Cruickshank1, Luis F Campesato1, Chien-Huan Weng1, Saeed Hemayat6, Chrysafis Andreou7, Ricardo Alvim1, Gregor Hutter2, Marjan Rafat8,9,10, Morteza Mahmoudi11.   

Abstract

Patients diagnosed with glioblastoma have poor prognosis. Conventional treatment strategies such as surgery, chemotherapy, and radiation therapy demonstrated limited clinical success and have considerable side effects on healthy tissues. A central challenge in treating brain tumors is the poor permeability of the blood-brain barrier (BBB) to therapeutics. Recently, various methods based on immunotherapy and nanotechnology have demonstrated potential in addressing these obstacles by enabling precise targeting of brain tumors to minimize adverse effects, while increasing targeted drug delivery across the BBB. In addition to treating the tumors, these approaches may be used in conjunction with imaging modalities, such as magnetic resonance imaging and positron emission tomography to enhance the prognosis procedures. This review aims to provide mechanistic understanding of immune system regulation in the central nervous system and the benefits of nanoparticles in the prognosis of brain tumors. This article is characterized under: Diagnostic Tools > in vivo Nanodiagnostics and Imaging Nanotechnology Approaches to Biology > Cells at the Nanoscale Nanotechnology Approaches to Biology > Nanoscale Systems in Biology.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  glioblastoma; imaging; immunoengineering; immunotherapy; nanomedicine

Mesh:

Year:  2019        PMID: 31407522     DOI: 10.1002/wnan.1575

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol        ISSN: 1939-0041


  2 in total

1.  Gain-Of-Function E76K-Mutant SHP2 Promotes Cell Proliferation, Metastasis, And Tumor Growth In Glioblastoma Through Activation Of The ERK/CREB Pathway.

Authors:  Fan Yang; Mo Xu; Shiqing Wang; Le Song; Dandan Yu; Yao Li; Rui Cao; Zhang Xiong; Zhijun Chen; Qian Zhang; Bing Zhao; Siying Wang
Journal:  Onco Targets Ther       Date:  2019-11-07       Impact factor: 4.147

2.  Immune-related lncRNAs, LINC01268 and CTB-31O20.2, as favorable prognostic markers for glioma inhibition.

Authors:  Dong-Hui Liu; Xiu Yang; Jian-Feng Guo; Han Meng; Shang-Hang Shen
Journal:  Transl Cancer Res       Date:  2022-04       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.